Evidence & regulatory context
- Mechanism
- Tin protoporphyrin: heme oxygenase inhibitor (no discrete ChEMBL MoA record); related analogue stannsoporfin reached trials
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Tin protoporphyrin IX; SnPP; Stannic protoporfin
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseIschaemia-reperfusionLimb / skeletal muscleCD-1Malen = Signalling study 32 mice in four groups of 8; glycerol acut…Intravenous tail vein bolus, with a separate intraperitoneal dose-response arm1 mg nitrited myoglobin plus 1 micromol tin protoporphyrin;…18 h before injury induction (preconditioning); signalling assessed 4 and 18 h…
Model: Several models: glycerol-induced rhabdomyolysis acute kidney injury (9 mL/kg of 50 per cent glycerol divided between the hind limbs), maleate nephrotoxicity (600 mg/kg intraperitoneally), 30 min left renal pedicle occlusion with assessment at two weeks, 25 min hepatic ischaemia, and glycerol-induced hepatotoxicity
The combination produced additive or synergistic increases in renal haem oxygenase 1, haptoglobin and interleukin 10 (up to 20-fold) without apparent toxicity, and conferred near-complete protection against glycerol and maleate acute kidney injury, reduced postischaemic renal mass loss from 38 to 1…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
